Treatment and Surveillance of Uterine Sarcomas

Adjuvant Radiotherapy and Systemic Therapy

The use of adjuvant radiotherapy (RT) in high-grade disease remains a subject of clinical debate. While RT may improve local pelvic control, evidence has not consistently demonstrated an improvement in overall survival (OS).

The recommendation for RT depends heavily on the stage:

• Stage I uLMS and UUS: Routine postoperative RT is not recommended; observation is the preferred approach.
• Stage II and III disease: Clinicians may consider adjuvant systemic therapy or External Beam Radiation Therapy (EBRT).

First-Line Systemic Therapy

For patients presenting with advanced, recurrent, or metastatic disease, several systemic regimens are available. First-line options include:

1. Single-agent doxorubicin.
2. Gemcitabine/docetaxel.
3. Doxorubicin/trabectedin (specifically recommended for LMS).
4. Eribulin (an option for advanced leiomyosarcoma).

Precision Medicine: Biomarker-Directed Therapy

The landscape of uterine sarcoma treatment is shifting toward molecularly targeted therapies. Identifying specific genetic alterations can provide life-extending options for patients with advanced disease.

Recurrence and Metastatic Management

Recurrence rates for uterine sarcomas are high, particularly for uLMS, which can range from 50% to 70%.

Local and Distant Recurrence

• Local Recurrences: These may be managed via surgical resection, which can be performed with or without Interstitial Radiation Therapy (IORT).
• Isolated Metastases: For resectable isolated metastatic lesions, surgical resection or ablative therapies, such as Stereotactic Body Radiation Therapy (SBRT), are appropriate.

Post-Treatment Surveillance Protocols

Because of the high risk of recurrence, rigorous surveillance is essential for early detection. Surveillance is divided into clinical examinations and radiological imaging.

Clinical and Imaging Schedule

The intensity of surveillance is highest in the first few years following treatment:

1. Clinical Exams: History and physical (H&P) examinations should be performed every 3–4 months for the first 2–3 years, transitioning to every 6–12 months thereafter.
2. Imaging:
   • Years 1–3: Chest/abdomen/pelvis CT scans every 3–6 months.
   • Years 4–5: CT scans every 6–12 months.
   • Depending on the specific histology and stage, additional annual or biannual imaging may be considered for up to 5 years.

Exam Tip: When calculating the frequency of surveillance, remember that the highest density of imaging and clinical visits occurs in the first 24–36 months post-treatment to capture early recurrences.

---

Disclaimer: This article is for educational purposes and is based on NCCN Guidelines Version 3.2026. Clinical decisions should always be made by qualified medical professionals.